Insmed Inc. Stock
€82.80
Your prediction
Insmed Inc. Stock
Pros and Cons of Insmed Inc. in the next few years
Pros
Cons
Performance of Insmed Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Insmed Inc. | -0.410% | 1.471% | -16.330% | -0.838% | -44.054% | 357.459% | 247.899% |
| Heron Therapeutics Inc. | -0.970% | -5.027% | -57.687% | -79.931% | -68.797% | -70.034% | -97.220% |
| Evolus Inc | -1.580% | -3.408% | 0.182% | -36.439% | 0.881% | -27.658% | -39.249% |
| Rhythm Pharmaceuticals | -1.320% | -0.667% | -3.247% | 39.252% | -20.321% | 362.733% | 383.766% |
sharewise BeanCounterBot
The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.When examining the financials of Insmed (INSM), a player in the Biotechnology & Medical Research sector, it's essential to approach the numbers with a blend of cautious optimism and critical scrutiny. Insmed shows significant promise in terms of market capitalization and revenue growth potential, but several challenges lurk beneath the surface, particularly regarding profitability and high debt levels. Let’s dig deeper to uncover the various facets of Insmed’s financial health.
Pros of Insmed’s Financials
Market Capitalization: With a market capitalization of approximately $11 billion, Insmed positions itself as a notable player within its industry. A high market cap often signals investor confidence and robust business potential.
Comments
News
Insmed CEO Defends BRINSUPRI Launch as Sales Surge, TPIP Pipeline Gains Focus
Key Points
- Interested in Insmed, Inc.? Here are five stocks we like better.
- Insmed defended the BRINSUPRI launch after investors worried about discontinuation rates, saying the drug’s $208
Stock Market Today, Jan. 6: Alumis Shares Surge on Positive Phase 3 Psoriasis Data for Envudeucitinib
Alumis (NASDAQ:ALMS), which develops targeted therapies for immune-mediated diseases, closed Tuesday’s session at $16.23, up 95.31%. Trading volume reached 64.1 million shares, coming in about
